HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Ap	pplication of:)	
O'Reilly et al.)	
Serial N	To. 10/042,347) Art Unit: 1642)	
		Examiner: Sheela J. Huff	
Filed:	January 11, 2002	RECEIVED)
For:	Nucleic Acid Molecules Encoding	AUG 1 5 2002	
	Endostatin Protein and Peptide)	
	Fragments Thereof	TECH CENTER 1600/290	DC

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

This Supplemental Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be required. However, if a first Office Action on the merits has issued, please consider this Information Disclosure Statement under 37 C.F.R. 1.97(c). The Commissioner is hereby authorized to charge the applicable fees, if any, to Deposit Account No. 11-0855.

> I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 08, 2002

> > Jamie L. Greene - Reg. No. 32,467

ATLLIB02 86774 1

The citation of this information does not constitute an admission of priority or that the cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Jamie L. Greene Reg. No. 32,467

KILPATRICK STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500 Our Docket: 05213-0880 (43170-249874) RECEIVED
AUG 1 5 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00) Approved for esc through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Across 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO Application No. 10/042,347 Filing Date 01/11/2002 **INFORMATION** First Named Inventor O'Reilly et al. STATEMENT BY APPLICANT Group Art Unit 1642 (use as many sheets as necessary) **Examiner Name** Sheela Jitendra Huff 1 Attorney Docket Number 05213-0880 (43170-249874) Sheet of 6 U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Where Cite Examiner Kind Code of Cited Document Relevant Passages or Name of Patentee or Initials No. Number⁴ (if known) Applicant of Cited Document MM-DD-YYYY Relevant Figures Appear 1 60/80728 MIXSON, James A. 06/27/2000

RECEIVED

AUG 1 5 2002

TECH CENTER 1600/2900

			Y
Examiner		Date	
Signature		Considered	
į.	1		l

for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

			AUG 1 2 2 T	, Comp	lete if Known
Substitute for Fe	rm 1449/A/PT	dig .	3 2002	Application No.	10/042,347
		VZ		Filing Date	01/11/2002
			KOISCEOSU		O'Reilly et al.
STATEMENT BY APPLICANT (use as many sheets as necessary)				Group Art Unit	1642
				Examiner Name	Sheela Jitendra Huff
Sheet	2	of	6	Attorney Docket Number	05213-0880 (43170-249874)
			·		

Sheet	·	2 or 6		Attorney Docket Num	03213-066	0 (+3170-249874)	
						RECEI	7
		OTHER PRIOR AF	RT - NON PAT	ENT LITERATURE I	OCUMENTS	, LOLI	V
Examiner Initials	Cite No.1		ournal, serial, symp	LETTERS), title of the article (osium, catalog, etc.), date, pag and/or country where publishe	e(s), volume-issue numb d	of the AUG 1 5 per(s).	ZUL
	2	Author:	Title: Chapter l	2: Vectors for Gene Therapy		ECH CENTER 1	60 0
	j	Publ:					
		Current Protocols in Human Genetics		Vol/Iss:	Pages:	Date: 1997	
	3	Author: BOUSSIF, O. et al.		le vector for gene and oligonuc vethylenimine	eleotide transfer into cell	s in culture andin	
		Publ: Proc. Natl. Acad. Sci. USA		Vol/Iss: 92	Pages: 7297-7301	Date: 08/1995	
	4	Author: CALOS, MICHELE P.	Title: The poter	ntial of extrachromosomal repl	icating vectors for gene t	therapy	
		Publ:	•				
		TIG		Vol/lss: 12 (11)	Pages: 463-466	Date: 11/1996	
	5	Author: CHEN, P. et al.	Title: Genetic N	Mechanisms of Tumor Suppres	sion by the Human p53 G	Gene	
		Publ:					
		Science		Vol/Iss: 250	Pages: 1576-1579	Date: 12/1990	
	6	Author: CHENG, PI-WAN		Ligand-Facilitated Gene Trans and Expression by Transferrin	sfer: Enhancement of Lip	osome-Mediated Gene	
		Publ: Human Gene Therapy		Vol/lss: 7	Pages: 275-282	Date: 02/10/199	
	7	Author: DARDIK, R. et al	Title: The struc	ture of endothelial cell thromb	ospondin - Characterizat	ion of the	
		Publ:	heparin-b	inding domains			
		Eur J Biochem		Vol/lss: 168 (2)	Pages: 347-355	Date: 10/15/198	
	8	Author: DEBS, R.J, et al.		on of Gene Expression in Vivo	by Liposome-mediated I	Delivery of a Purified	
		The Journal of Biological Chemistry		Vol/Iss: 265 (18)	Pages: 10189-10192	Date: 06/25/199	

		-
Examiner	Date	
Signature	 Considered	

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

AUG 1 3 2002 Complete if Known Application No. 10/042,347 Substitute for Form 1449/A/ 01/11/2002 Filing Date INFORMATION DE CLOSURE First Named Inventor O'Reilly et al. STATEMENT BY APPLICANT Group Art Unit 1642 (use as many sheets as necessary) **Examiner Name** Sheela Jitendra Huff Attorney Docket Number Sheet of 05213-0880 (431 3 6 CEIVED AUG 1 5 2002 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number TECH CENTER 1600/2900 Examiner Cite Initials Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation Author: DIXIT, V.M. et al. Publ: Proc. Natl. Acad. Sci. USA Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985 Author: FAN et al. Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of Publ: Trends in Pharmacolgical Sciences Vol/Iss: 16(2) Pages: 57-66 Date: 02/95 Author: FIDLER et al. Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis Publ: Cell Vol/Iss: 79(2) Pages: 185-188 Date: 10/21/94 Title: Induction of Chemosensitivity in Human Lung Caner Cells in Vivo by Author: FUJIWARA, T. et al. 12 Adenovirus-mediated Transfer of the Wild-Type p53 Gene Publ: Cancer Research Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199 Title: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer Author: GOLDMAN, C.K. et al. Nature Biotechnology Vol/Iss: 15 Pages: 462-466 Date: 05/1997 Title: Clinical trials of antiangiogenic agents Author: HAWKINS, MICHAEL J. M.D. Publ: <u>'urrent Opinion in Oncology</u> Voi/Iss: 7 Pages: 90-93 Date: 1995 Author: KING, RALPH P. Jr. Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block 15 Publ: Wall Street Journal Date: 11/12/199 Vol/Iss: Pages: A1, A8

		I .	
Examiner		Date	
Signature	One Con	Considered	

App. 4 for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

		AUG 1 3 2002 h	Comp	lete if Known
Substitute	for Fo	m 1449/A/P102	Application No.	10/042,347
		To a definition of the second	Filing Date	01/11/2002
		DRMATION TUSELOSURE	First Named Inventor	O'Reilly et al.
S	STA	FEMENT BY APPLICANT	Group Art Unit	1642
		(use as many sheets as necessary)	Examiner Name	Sheela Jitendra Huff
Sheet	1	4 of 6	Attorney Docket Number	05213-0880 (1170249174) VED
			·	AUG 1 5 2002
		OTHER PRIOR ART - NON PATI	ENT LITERATURE DOC	
Examiner Initials	Cite No.1		ETTERS), title of the article (when sium, catalog, etc.), date, page(s), vind/or country where published	appropriate), (TECHeCENTER 1600/290)
	16		on of a New Cell Adhesion Motif in minal Cell Binding Domain on Hun	Two Homologous Peptides from the nan Thrombospondin
	:	Publ: The Journal of Biological Chemistry	W-1/1 2/0/12	2202 0214 D 4 4000
		The Journal of Biological Chemistry	Vol/lss: 268 (12) Pa	ges: 8808-8814 Date: 1993
	17	Author: LESOON-WOOD, L.A. et al. Title: Systemic C Human Br	Gene Therapy with p53 Reduces Gro east Tumor in Nude Mice	owth and Metastases of a Malignant
		Human Gene Therapy	Vot/Iss: 6 Pa	ges: 395-405 Date: 04/1995
	18		r Heparin and Retains Potent Angio	alogue of Platelet Factor 4 That Lacks static Activity ges: 2077-2083 Date: 04/15/199
	19	Author: MARSHALL, ELIOT Title: Gene Ther.	apy's Growing Pains	
		Publ:		
		<u>Science</u>	Vol/lss: 269 Pa	ges: 1050-1055 Date: 08/25/199
·	20	Author: O'REILLY et al. Title: Endostatin	: An Endogenous Inhibitor of Angio	ogenesis and Tumor Growth
		Publ:		
		Cell	Vol/lss: 88 Pa	ges: 277-285 Date: 01/24/97
	21			nunoliposomeplasmid complexes for
	i	Publ: Proceedings of the American Association for Cancer Resea	nd selective gene therapy rch Vol/iss: 38 Pa	ges: 342 Date: 03/1997
	22	Author: PASQUALINI, R. et al. Title: av Integri	ns as recptors for tumor targeting	by circulating ligands
		Publ:		
		Nature Biotechnology	Vol/lss: 15 Pa	ges: 542-546 Date: 06/1997

Examiner	Date	-
Signature	Considered	

¹Unique citation designation number. ¹See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ¹Applicant is to place a check mark here if English language translation is attached

for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

AUG 1 2 20 CT				· Complete if Known						
Substitute	for For	m 1449/A/P	PZ.	. 5 2002 ,	1	Application No	10/042.34	7	··· ·	
_			VI.		/ 	Filing Date	01/11/200	2		
INFORMATION DISCLOSURE					First Named Inventor	O'Reilly e	t al.			
STATEMENT BY APPLICANT						Group Art Unit	1642			
(use as many sheets as necessary)				ieets as necessary)	Examiner Name	Sheela Jite	Sheela Jitendra Huff			
Sheet		5	of	6		Attorney Docket Numl	ber 05213-088	30 (43170-24	19874)	
Examiner Initials	Cite No. ¹				, journal, serial, sym	LETTERS), title of the article (posium, catalog, etc.), date, pag y and/or country where publishe	e(s), volume-issue num	ber(s),	AUG 1 5	_T ,21
Initials	No.		1101	i (oook, magazine,						
	23	Author: PA	\SQU _i	ALINI, R. et al.	Title: Organ ta	argeting in vivo using phage disp	olay peptide libraries	TECH	CENTER	10
		Publ:								l
		Nature				Vol/lss: 380	Pages: 364-166	Date: 0	03/28/199	
	24	Author: SA	dKI et	al.		on of Tumor Ahgiogenesis by a		Polypeptide	e Containing	
		Publ:			the Arg-	Gly-Asp (RGD) Sequence of Fi	bronectin, Poly(RGD)			
		Jpn. J. Canc	er Res	earch		Vol/Iss: 81	Pages: 668-675	Date:	1990	1

Title: Overexpression of p21WAF1/CIP1 induces frowth arrest, giant cell formation and

Pages: 1899-1905

Date:

1995

apoptosis in human breast carcinome cell lines

Vol/Iss: 11

Author: TANAKA, T. et al. Publ: Nature Medicine Vol/Iss: 3 Pages: 437-442 Date: 04/1997 Author: WEINSTAT-SASLOW, D.L. et al. Publ: Cancer Research Vol/Iss: 54 Pages: 6504-6511 Publ: Molecular Genetics and Metabolism Vol/Iss: 64 Pages: 001-005 Date: 1998 Pages: 437-442 Date: 04/1997 Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiongangesis Vol/Iss: 54 Pages: 6504-6511 Date: 1994 Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes Vol/Iss: 64 Pages: 001-005 Date: 1998 Publ: Molecular Genetics and Metabolism Vol/Iss: 63 Pages: 103-109 Date: 1998			· · · · · · · · · · · · · · · · · · ·							
Author: WEINSTAT-SASLOW, D.L. et al. Publ: Cancer Research Author: XU, M. et al. Publ: Molecular Genetics and Metabolism Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Cancer in Vivo Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Cancer in Vivo		26	Publ:	Title:	angiogenesis and tumor growth	·				
et al. Publ: Cancer Research Vol/Iss: 54 Pages: 6504-6511 Date: 1994 Author: XU, M. et al. Publ: Molecular Genetics and Metabolism Vol/Iss: 64 Pages: 001-005 Date: 1998 Publ: Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Cancer in Vivo			Nature Medicine		Vol/iss: 3	Pages: 43/-442	Date:	04/199/		
Author: XU, M. et al. Publ: Molecular Genetics and Metabolism Vol/Iss: 64 Pages: 001-005 Date: 1998 Author: XU, M. et al. Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes Vol/Iss: 64 Pages: 001-005 Date: 1998 Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Cancer in Vivo		27	et al.	Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and						
Publ: Molecular Genetics and Metabolism Vol/Iss: 64 Pages: 001-005 Date: 1998 29 Author: XU, M. et al. Publ: Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Cancer in Vivo			Cancer Research		Vol/Iss: 54	Pages: 6504-6511	Date:	1994		
29 Author: XU, M. et al. Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Cancer in Vivo		28	·	Title:	• • • • • • • • • • • • • • • • • • • •					
Cancer in Vivo	<u></u> _		Molecular Genetics and Metabolism		Vol/Iss: 64	Pages: 001-005	Date:	1998		
Molecular Genetics and Metabolism Vol/lss: 63 Pages: 103-109 Date: 1998		29		Title:		t of Thrombospondin I Ir	hibits Hun	nan Breat		
			Molecular Genetics and Metabolism		Vol/Iss: 63	Pages: 103-109	Date:	1998		

Author: SHEIKH et al.

Publ: Oncogene

Examiner Date Considered ¹Unique citation designation number | See attached Kinds of U.S. Patent Documents | ¹Enter Office that issued the document, by the two-letter code

PTO/SB/08A (08-00)

Appl 2d for use through 10/31/2002 OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known 1 3 2002 Application No. 10/042,347 Substitute for Form 1449/A/PTO Filing Date 01/11/2002 INFORMATIONOLISE First Named Inventor O'Reilly et al. STATEMENT BY APPLICANT 1642 Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheela Jitendra Huff 05213-0880 (43170-249874) Sheet 6 of 6 Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No. publisher, city and/or country where published Title: Parenteral Gene Therapy with p53 Inhibits Human Breat Tumors In Vivo Through a Author: XU, M. et al. 30 Bystander Mechanism Without Evidence of Toxicity Publ: Human Gene Therapy Vol/Iss: 8 Pages: 177-185 Date: 01/20/199 Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT Publ: PROCRESSION IN MELANOMA, LUNC AND RREAST CARCINOMA CELL Int. J. Cancer Vol/Iss: 59 Pages: 191-195 Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Author: ZHU, N. et l. Publ: <u>Science</u> Vol/Iss: 261 Pages: 209-211 Date: 07/09/199

RECEIVED

AUG 1 5 2002

TECH CENTER 1600/2900

Examiner	Date	
Signature	 Considered	